One not like the other: The weakness of the blood sugar-MAFLD analogy
- PMID: 34678406
- DOI: 10.1016/j.jhep.2021.10.010
One not like the other: The weakness of the blood sugar-MAFLD analogy
Conflict of interest statement
Conflict of interest The authors declare no competing interests or any conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".J Hepatol. 2022 Feb;76(2):484-485. doi: 10.1016/j.jhep.2021.11.003. Epub 2021 Nov 11. J Hepatol. 2022. PMID: 34774637 No abstract available.
Comment on
-
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.J Hepatol. 2021 Aug;75(2):454-461. doi: 10.1016/j.jhep.2021.05.003. Epub 2021 May 19. J Hepatol. 2021. PMID: 34019941
-
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.J Hepatol. 2021 Dec;75(6):1284-1291. doi: 10.1016/j.jhep.2021.07.035. Epub 2021 Aug 8. J Hepatol. 2021. PMID: 34380057
-
Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change.J Hepatol. 2021 Dec;75(6):1267-1270. doi: 10.1016/j.jhep.2021.08.020. Epub 2021 Aug 28. J Hepatol. 2021. PMID: 34464658 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
